Single-agent thalidomide therapy elicits partial responses and stable disease in a significant number of patients with renal cell carcinoma.
Dr. Robert Amato, from the Scott Department of Urology at Baylor College of Medicine in Houston, Texas, United States, presented a summary of published phase II thalidomide trials, as well as new data on phase I/II combination regimens for renal cell carcinoma, at the Chemotherapy Foundation Symposium here November 14.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!